1,25(OH)2D3 in Brain Function and Neuropsychiatric Disease
Florian Langa Ke Mab Christina B. Leibrockc
aDepartment of Physiology, Eberhard-Karls-University of Tübingen, Germany, bDepartment of Pharmacology, Experimental Therapy & Toxicology, Eberhard-Karls-University of Tübingen, Germany, cFresenius Kabi Deutschland GmbH, Bad Homburg, Germany
Key Words
Calcitriol • Klotho • Neuron • Cerebral • Prefrontal cortex • Hippocampus • Cingulate gyrus • Thalamus • Hypothalamus • Substantia nigra • Behavior • Multiple sclerosis • Parkinson´s disease • Alzheimer´s disease • Anxiety • Depression • Bipolar disorder • Schizophrenia
Abstract
1,25(OH)2D3 (1,25-dihydroxy-vitamin D3 = calcitriol) is a powerful regulator of mineral metabolism. The hormone increases calcium and phosphate plasma concentrations in part by stimulation of intestinal absorption and renal reabsorption of calcium and phosphate. It is primarily, but not exclusively, produced in the kidney. Renal 1,25(OH)2D3 formation is stimulated by calcium and phosphate deficiency and by parathyroid hormone which is up-regulated by hypocalcemia. 1,25(OH)2D3 formation is inhibited by fibroblast growth factor FGF23, which is up-regulated by phosphate excess and requires Klotho to become effective. Klotho- or FGF23-deficiency leads to excessive plasma 1,25(OH)2D3-, Ca2+- and phosphate-concentrations with severe soft tissue calcification and accelerated aging. Tissue calcification and premature aging are prevented by NH4Cl without affecting 1,25(OH)2D3-formation. 1,25(OH)2D3 has powerful effects apparently unrelated to mineral metabolism, including anti-inflammatory actions and modification of multiple brain functions. Excessive 1,25(OH)2D3 formation in klotho-deficient NH4Cl-treated mice leads to an amazing surge of exploratory behavior, lack of anxiety and decreased depression, effects dissipated by low vitamin D diet. Conversely, vitamin D deficient mice display reduced explorative behavior, enhanced anxiety, aberrant grooming, submissive social behavior, social neglect and maternal cannibalism. 1,25(OH)2D3 is generated in human brain, and acts on diverse structures including prefrontal cortex, hippocampus, cingulate gyrus, thalamus, hypothalamus, and substantia nigra. In neurons 1,25(OH)2D3 suppresses oxidative stress, inhibits inflammation, provides neuroprotection, down-regulates a variety of inflammatory mediators and up-regulates a wide variety of neurotrophins. Diseases postulated to be favorably modified by 1,25(OH)2D3 include multiple sclerosis, Parkinson´s disease, Alzheimer´s disease, depression, bipolar disorder and schizophrenia. Clearly, substantial additional experimentation is required to fully understand the neuro-psycho-pathophysiological role of 1,25(OH)2D3 and to exploit 1,25(OH)2D3 or related agonists in the treatment of neuro-psychiatric disorders.
Introduction
Calcitriol or 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3), a hormone generated from the vitamin D metabolite 25(OH)D3 (25-hydroxy-vitamin D3), is one of the major regulators of mineral metabolism [1-3] effective in part by stimulation of intestinal and renal Ca2+ and phosphate transport [1, 3]. 1,25(OH)2D3 can be generated from vitamin D by hydroxylation to 25(OH)D3 [1, 2] and second hydroxylation to 1,25(OH)2D3 [1, 2, 4]. The second decisive hydroxylation is accomplished by a 25-hydroxyvitamin D3 1α-hydroxylase (1α-hydroxylase) [1, 2, 5]. The renal 25-hydroxyvitamin D3 1α-hydroxylase is under tight control [1, 2, 5]. It is up-regulated by calcium- and phosphate deficiency and parathyroid hormone [2, 3, 6, 7]. 25-hydroxyvitamin D3 1α-hydroxylase is inhibited by fibroblast growth factor 23 (FGF23) [3, 8], an effect requiring the co-receptor Klotho [9]. The FGF23 released from bone is stimulated by excess phosphate and disrupts further 1,25(OH)2D3 formation and phosphate accumulation [8, 10, 11]. The fine tuning of renal 1α-hydroxylase aims to adjust the 1,25(OH)2D3 formation exactly to the requirements of mineral metabolism. However, the components are sensitive to factors unrelated to mineral metabolism. For instance, 1,25(OH)2D3 formation is further up-regulated by dehydration [12] and inhibited by CO-releasing molecule 2 (CORM-2) [13], FGF23 is up-regulated by 1,25(OH)2D3, phosphate excess, Ca2+, PTH, leptin, catecholamines, mineralocorticoids, volume depletion, lithium, high fat diet, iron deficiency, tumor necrosis factor alpha (TNFα.
1,25(OH)2D3 contributes to the regulation of multiple functions seemingly unrelated to mineral metabolism, such as suicidal cell death [18-24], inflammation and immune response [25-28], glucose metabolism [29], platelet activation [30], neuroprotection and multiple brain functions [31] including mood [32, 33]. Along those lines 25-hydroxyvitamin D3 1α-hydroxylase is expressed and thus 1,25(OH)2D3 produced in several extra-renal tissues including dendritic cells/macrophages, skin (keratinocytes, hair follicles), lymph nodes (granulomata), thymus, placenta, lung, colon (epithelial cells and parasympathetic ganglia), stomach, pancreatic islets, adrenal medulla, and brain (pericytes, cerebellum and cerebral cortex) [34-42], Neurons can possibly transform the inactive cholecalciferol into 25(OH)D3, which is activated to 1,25(OH)2D3, by neurons or microglia [43]. 1,25(OH)2D3 enters neuronal nuclei and is thus expected to modify neuronal gene expression [44]. In view of its neuronal effects it is considered as a neurosteroid [43].
Effect of excessive 1,25(OH)2D3 formation in klotho deficient mice on brain function
Klotho is not only expressed in the kidney, but is highly expressed as well in choroid plexus of the brain [9]. The extracellular domain of the transmembrane protein may be cleaved off and enter blood or cerebrospinal fluid [9]. Negative 1α-hydroxylase regulation by FGF23 is disrupted by klotho-deficiency [9, 45, 46]. Consequences of subsequent excessive formation of 1,25(OH)2D3 include hyperphosphatemia and severe soft tissue calcification eventually leading to diverse age related disorders including vascular calcifications, thymus atrophy, pulmonary emphysema, hypoglycemia, infertility, skin thinning, osteoporosis, sarcopenia, hypoactivity, hearing loss, and ataxia [9, 45, 46] as well as severe reduction of life span [9, 45]. Conversely, klotho overexpression in mice extends the life span [47]. By the same token life span of humans is affected by specific klotho gene variants [48]. Tissue calcification and premature aging is prevented by ammonium chloride (NH4Cl) treatment, which disrupts osteogenic signaling and almost normalizes the lifespan of klotho deficient mice without affecting excessive 1,25(OH)2D3-formation [49, 50]. NH4Cl has been shown to be effective by alkalinizing acidic cellular compartments thus disrupting TGFß maturation [49]. Unlike the severely ill untreated klotho-deficient mice, NH4Cl treated klotho deficient mice are able to undergo behavioral studies [50].
Excessive 1,25(OH)2D3 formation in klotho deficient mice leads to profound behavioral effects [50]. Open field, dark-light box, and O-maze revealed significantly higher exploratory behavior in NH4Cl-treated klotho-deficient mice than in NH4Cl-treated or untreated wild-type mice, differences abrogated by low vitamin D diet (LVD). Moreover, the time of floating in the forced swimming test was significantly shorter in NH4Cl-treated klotho-deficient mice on standard diet than in untreated wild-type mice or NH4Cl-treated klotho-deficient mice on LVD. The altered behavior of NH4Cl-treated klotho-deficient mice thus resulted from excessive 1,25(OH)2D3 formation and were not due to behavioral effects of klotho or of NH4Cl treatment [50]. Nevertheless, those observations do not exclude a more direct role of klotho in the regulation of depression and cognitive function [51-55], oligodendrocyte maturation and myelination [56] as well as neurodegeneration [57]. Klotho is apparently required for the suppressive effect of fibroblast growth factor 21 (FGF21) on sugar or alcohol preference/addiction [58-63].
Effects of vitamin D deficiency on murine behavior
Vitamin D deficiency of mice has been shown to reduce explorative behavior and enhance anxiety, aberrant grooming, submissive social behavior, social neglect and maternal cannibalism [64-66]. Vitamin D deficiency before birth impacts on murine self-grooming [67]. Murine behavior is similarly affected by deletion of the vitamin D receptor (VDR) [65, 68-73].
Evidence for impact of 1,25(OH)2D3 in human brain function
In human brain, VDR and vitamin D metabolizing enzymes are expressed by several cerebral structures including prefrontal cortex, hippocampus, cingulate gyrus, thalamus, hypothalamus, and substantia nigra [36]. VDR gene variants are associated with altered behavior [74, 75] as well as susceptibility to age-related changes in cognitive function and depressive symptoms [74].
Similar to observations in mice, 1,25(OH)2D3 has been shown to affect human behavior [32, 33], emotions and anxiety [76]. Vitamin D deficiency fosters the development of several psychiatric diseases including depression, bipolar disorder and schizophrenia [76-79]. 1,25(OH)2D3 serum concentrations correlate with extraversion [80], which is in turn negatively correlated with social phobia, cluster C personality disorders and suicide risk [79, 81]. In patients suffering from depression decreased serum levels of 25(OH)D3 presumably compromising 1,25(OH)2D3 formation have been reported [82, 83]. Conversely, vitamin D supplementation has been shown to reduce depressive symptoms [84-86]. Seasonal variations of sun exposure presumably leading to respective alterations of cutaneous vitamin D formation and 1,25(OH)2D3 production have been associated with seasonal affective disorders [84-86] and vitamin D deficiency may contribute to the desynchronisation in those disorders [87]. Vitamin D deficiency during brain development has been identified as a risk factor for the development of schizophrenia, a condition associated with enhanced neuroticism and decreased extraversion [88]. Conversely vitamin D supplementation has been reported to decrease the risk of developing psychotic-like symptoms [78]. VDR-regulated genes presumably contribute to the pathophysiology of ±3, 4-methylenedioxymethamphetamine (ecstacy) intoxication, which may, at least in theory, be suppressed by vitamin D supplementation [89].
1,25(OH)2D3 in neuroinflammation
In experimental autoimmune encephalomyelitis, a murine model for multiple sclerosis, 1,25(OH)2D3 treatment suppresses inflammation, demyelination as well as neuron loss [90, 91] and increases numbers of neural stem cells, oligodendrocyte precursor cells as well as oligodendrocytes [90], effects accomplished in part by down-regulation of pro-inflammatory interferon gamma (IFN-γ), granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 17A (IL-17A) as well as up-regulation of anti-inflammatory interleukin 4 (IL-4) and interleukin 10 (IL-10) [90]. 1,25(OH)2D3 thus decreases the T-cell responsiveness to Myelin-Derived Antigens [92]. 1,25(OH)2D3 further blunts lipopolysaccharide (LPS)-induced nitrite formation, reactive oxygen species (ROS) production and interleukin 6 (IL-6) as well as macrophage inflammatory protein 2 (MIP-2) release [93]. Signaling involved includes up-regulation of Beclin1, increased B-cell lymphoma 2 Bcl-2)/
Bcl-2-associated X protein (Bax) ratio, and decreased accumulation of
lipid modified form of microtubule-associated proteins 1A/1B light chain 3B (LC3-II) [91]. Selective
synthetic VDR agonists with relatively small calcemic effect, such as
paricalcitol, maxacalcitol, doxercalciferol, and
falecalcitriol [94-98], may be particularly interesting for the use in neuropsychiatric
disorders. However, still little is known about their effects on cerebral
function. Paricalcitol has been shown to exert anti-convulsive and
anti-depressive effects [99, 100]. Maxacalcitol, paricalcitol,
and doxercalciferol decrease Aβ-production
and increase Aβ-degradation in neuroblastoma
cells or vitamin D deficient mouse brains [101] and are, thus, candidates for
the treatment of Alzheimer´s disease. Clearly, much still needs to be learned
about cerebral effects and side effects of this interesting group of drugs. Mechanisms
invoked in the effects of 1,25(OH)2D3 on brain function Several
mechanisms have been suggested to participate in the cerebral effects of 1,25(OH)2D3,
including suppression of oxidation, inhibition of inflammation, counteraction
of vascular injury, up-regulation of neurotrophins and improvement of metabolic
and cardiovascular function [32, 102]. 1,25(OH)2D3
stimulates neuronal cell growth, survival, and proliferation [102]. It supports
proliferation of neural stem cells and their differentiation to
oligodendrocytes, effects paralleled by expression of neurotrophin 3 (NT-3), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF)
and ciliary neurotrophic factor (CNTF),
important neurotrophic factors for neural cell survival and differentiation [103].
Vitamin D deficiency has been suggested to affect cellular development,
dopamine transport and metabolism, as well as brain morphology [104]. 1,25(OH)2D3 fosters differentiation of dopaminergic neurons [102, 105, 106], an effect paralleled by up-regulation of N-cadherin [106]. Vitamin D increases expression of tyrosine hydroxylase and catechol-O-Methyltransferase (COMT) [105, 106], dopamine synthesis and metabolism [102, 105, 106], as well as expression of GDNF and its receptors, which is crucial for the survival of dopaminergic neurons [107]. 1,25(OH)2D3 decreases the expression of Neurogenin-2 (NEUROG2), a marker of immature dopaminergic neurons [105].
1,25(OH)2D3 further stimulates the neuronal formation of the neuroprotective cytokine IL-34 [108]. 1,25(OH)2D3 upregulates the Amyloid beta (Aβ) – scavenger receptor low density lipoprotein receptor related protein (LRP-1) [109] and reduces amyloid beta toxicity in part by enhancing sphingosine kinase activity and thus the sphingosine-1-phosphate (S1P)/ceramide (Cer) ratio [110]. 1,25(OH)2D3 decreases activities of p38 mitogen-activated protein kinases (p38-MAPK),
extracellular signal-regulated kinases (ERK), and
c-Jun N-terminal kinase (JNK) activation [93] and
endoplasmatc reticulum (ER) stress damage apparent from the ratio p38-MAPK/a
ctivating transcription factor 4 (ATF4) [110]. In neuroblastoma cells, 1,25(OH)2D3 decreases cell proliferation, changes cell morphology, increases expression of protein markers of mature neuronal cells [111], increases expression of nerve growth factor (NGF) [111], up-regulates transforming growth factor-beta2 (TGF-beta2) [112], stimulates protein kinase C (PKC) activity [112], and decreases myc expression [113].
At least in theory, 1,25(OH)2D3 could modify neuronal function by affecting neuronal or glial cytosolic Ca2+ activity [44, 114-116]. 1,25(OH)2D3-dependent calcium binding protein has been observed in nuclei influencing the pineal gland [117]. 1,25(OH)2D3 may suppress cerebral effects of glucocorticoids, which contribute to the development of major depression [118].
In other cell
types, VDR has been shown to modify the expression of 500-1000 genes engaged in
the regulation of a wide variety of cellular
functions including transport, growth, differentiation, and apoptosis [119,
120]. VDR-regulated genes in the hippocampus include CCAAT/enhancer-binding
protein beta (CEBPB), CD3e molecule, epsilon (CD3E) Calcium/Calmodulin Dependent Protein Kinase II Inhibitor 2, (CAMK2N2),
Krueppel-like factor 1 i (KLF1),
peripheral myelin protein 22 (PMP22),
Poly(A) Binding Protein Cytoplasmic 1 (PABPC1),
Plasma membrane calcium-transporting ATPase 3 (ATP2B3),
Glutamate receptor AMPA 3 (GRIA3), solute
carrier family 4 (Na+,HCO3- cotransporter)
member 4 (SLC4A4) Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2), retinoblastoma-binding protein 6 (E3 ubiquitin ligase)
(RBBP6), Latrophilin 1 (LPHN1), DNA Methyltransferase 3 Alpha (DNMT3A),
Tenascin R (TNR), and glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A)
[89]. However, the role of specific VDR-regulated genes in cerebral function remained
largely elusive. Conclusions
and future directions 1,25(OH)2D3
is generated by and has powerful effects on neurons. The hormone suppresses
oxidative stress, inhibits inflammation, provides neuroprotection, and modifies
a variety of neuronal and glial cell functions. It is effective in part by
down-regulation of inflammatory mediators and up-regulation of neurotrophins. A
variety of common diseases are presumably sensitive to 1,25(OH)2D3
including multiple sclerosis, Parkinson´s disease, Alzheimer´s disease,
depression, bipolar disorder and schizophrenia. Clearly, substantial additional
experimentation is required to fully understand the pathophysiological role of 1,25(OH)2D3
in those and further clinical conditions and to exploit 1,25(OH)2D3
or synthetic VDR-agonists in the treatment of neuropsychiatric disease. Future
studies dissecting effects of 1,25(OH)2D3 or synthetic
VDR-agonists on function of neurons and glial cells, on murine behavior and
cerebral function, as well as on the course of murine neuroinflammation are
expected to uncover novel therapeutic opportunities, future neuropsychiatric
analysis of patients treated with 1,25(OH)2D3 or
synthetic VDR-agonists are expected to define therapeutic efficacy and side
effects in the respective patients. Disclosure
Statement The authors
declare they have no conflict of interests. References 1 Basit,
S., Vitamin D in health and disease: a literature review. Br J Biomed Sci
2013;70:161-172. 2 Liberman, U.A., Disorders in vitamin D action, in Endotext
[Internet] 2014; MDText. com, Inc. 3 Olmos-Ortiz, A., et al., Regulation of calcitriol
biosynthesis and activity: focus on gestational vitamin D deficiency and
adverse pregnancy outcomes. Nutrients 2015;7:443-480. 4 Almilaji, A., et al., Regulation of the Voltage Gated K+
Channel Kv13 by Recombinant Human Klotho Protein. Kidney Blood Press Res
2014;39:609-622. 5 Zehnder, D. and M. Hewison, The renal function of
25-hydroxyvitamin D3-1α-hydroxylase. Mol Cell Endocrinol
1999;151:213-220. 6 Latus, J., et al., Analysis of α-Klotho, fibroblast
growth factor-, vitamin-D and calcium-sensing receptor in 70 patients with
secondary hyperparathyroidism. Kidney Blood Press Res 2013;37:84-94. 7 Rodriguez, M., E. Nemeth, and D. Martin, The
calcium-sensing receptor: a key factor in the pathogenesis of secondary
hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F253-264. 8 Bergwitz, C. and H. Juppner, Regulation of phosphate
homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010;61:91-104. 9 Kuro-o, M., Klotho, phosphate and FGF-23 in ageing and
disturbed mineral metabolism. Nature Reviews Nephrology 2013;9:650. 10 Borst, O., et al., CXCL16 is a novel diagnostic marker
and predictor of mortality in inflammatory cardiomyopathy and heart failure.
Int J Cardiol 2014;176:896-903. 11 Hu, M.C., et al., Fibroblast growth factor 23 and Klotho:
physiology and pathophysiology of an endocrine network of mineral metabolism.
Annu Rev Physiol 2013;75:503-533. 12 Abed, M., et al., Sensitization of erythrocytes to
suicidal erythrocyte death following water deprivation. Kidney Blood Press
Res 2013;37:567-578. 13 Feger, M., et al., Effect of carbon monoxide donor CORM-2
on vitamin D3 metabolism. Kidney Blood Press Res 2013;37496-505. 14 Fakhri, H., et al., Regulation of mineral metabolism by
lithium. Pflügers Archiv-European Journal of Physiology 2014;466:467-475. 15 Zhang, B., et al., Lithium-sensitive store-operated Ca2+
entry in the regulation of FGF23 release. Neurosignals 2015;23:34-48. 16 Lang, F., et al., Phosphate Homeostasis, Inflammation and
the Regulation of FGF-23. Kidney Blood Press Res 2018;43:1742-1748. 17 Bar, L., et al., Regulation of fibroblast growth factor
23 (FGF23) in health and disease. FEBS Lett 2019;593:1879-1900. 18 Cakici, C., et al., Dose-dependent effects of vitamin
1,25(OH)2D3 on oxidative stress and apoptosis. J Basic Clin Physiol Pharmacol
2018;29:271-279. 19 Chiang, K.C., et al., 1alpha,25(OH)2D3 Analog, MART-10,
Inhibits Neuroendocrine Tumor Cell Growth Through Induction of G0/G1
Cell-cycle Arrest and Apoptosis. Anticancer Res 2016;36:3307-3313. 20 Miao, D. and A. Scutt, Recruitment, augmentation and apoptosis
of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with
1,25-dihydroxyvitamin D3 in vivo. BMC Musculoskelet Disord 2002;3:16. 21 Narvaez, C.J. and J. Welsh, Differential effects of
1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and
apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology
1997;138:4690-4698. 22 Simboli-Campbell, M., et al., Comparative effects of
1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast
cancer cells. Breast Cancer Res Treat 1997;42:31-41. 23 Zhang, C.J., et al., Effects of 1,25(OH)2D3 on
proliferation and apoptosis of human glomerular mesangial cells. Am J Transl
Res 2016;8:2659-2666. 24 Zhang, J. and Z. Yao, Effect of 1,25(OH)2D3 on the growth
and apoptosis of breast cancer cell line MCF-7. Chin Med J (Engl)
2000;113:124-128. 25 Cantorna, M.T., et al., Vitamin D status,
1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr
2004;80:1717S-1720S. 26 Deluca, H.F. and M.T. Cantorna, Vitamin D: its role and
uses in immunology. FASEB J 2001;15:2579-2585. 27 Haroon, M. and O. Fitzgerald, Vitamin D and its emerging
role in immunopathology. Clin Rheumatol 2012;31:199-202. 28 Heine, G., et al., 1,25-dihydroxyvitamin D promotes IL-10
production in human B cells. Eur J Immunol 2008;38:2210-2218. 29 Reis, A.F., O.M. Hauache, and G. Velho, Vitamin D
endocrine system and the genetic susceptibility to diabetes, obesity and
vascular disease. A review of evidence. Diabetes Metab 2005;31:318-325. 30 Borst, O., et al., 1,25 (OH) 2 vitamin D3-dependent
inhibition of platelet Ca2+ signaling and thrombus formation in
klotho-deficient mice. FASEB J 2014;28:2108-2119. 31 Cui, X., et al., Vitamin D and the brain: Genomic and
non-genomic actions. Mol Cell Endocrinol 2017;453:131-143. 32 Cherniack, E.P., et al., Some new food for thought: the
role of vitamin D in the mental health of older adults. Curr Psychiatry Rep
2009;11:12. 33 Schaller, M. and D.R. Murray, Pathogens, personality, and
culture: Disease prevalence predicts worldwide variability in sociosexuality,
extraversion, and openness to experience. J Pers Soc Psycho 2008;95:212. 34 Diesel, B., et al., Towards a complete picture of splice
variants of the gene for 25-hydroxyvitamin D31alpha-hydroxylase in brain and
skin cancer. J Steroid Biochem Mol Biol 2004;89-90:527-532. 35 El-Atifi, M., et al., Expression of CYP2R1 and VDR in
human brain pericytes: the neurovascular vitamin D autocrine/paracrine model.
Neuroreport 2015;26:245-248. 36 Eyles, D.W., et al., Distribution of the vitamin D
receptor and 1α-hydroxylase in human brain. J Chem Neuroanat
2005;29:21-30. 37 Hewison, M., et al., Differential regulation of vitamin D
receptor and its ligand in human monocyte-derived dendritic cells. J Immunol
2003;170:5382-5390. 38 Hewison, M., et al., Vitamin D-mediated hypercalcemia in
lymphoma: evidence for hormone production by tumor-adjacent macrophages. J
Bone Miner Res 2003;18:579-582. 39 Radermacher, J., et al., Expression analysis of CYP27B1
in tumor biopsies and cell cultures. Anticancer Res 2006;26:2683-2686. 40 Segersten, U., et al., 25-hydroxyvitamin
D-1alpha-hydroxylase expression in normal and pathological parathyroid
glands. J Clin Endocrinol Metab 2002;87:2967-2972. 41 Smolders, J., et al., Expression of vitamin D receptor
and metabolizing enzymes in multiple sclerosis-affected brain tissue. J
Neuropathol Exp Neurol 2013;72:91-105. 42 Zehnder, D., et al., Extrarenal expression of
25-hydroxyvitamin d-1 alpha-hydroxylase. J Clin Endocrinol Metab
2001;86:888-894. 43 Landel, V., et al., Differential expression of vitamin
D-associated enzymes and receptors in brain cell subtypes. J Steroid Biochem
Mol Biol 2018;177:129-134. 44 Stumpf, W.E., et al., Brain target sites for
1,25-dihydroxyvitamin D3. Science 1982;215:1403-1405. 45 Kuro-o, M., et al., Mutation of the mouse klotho gene
leads to a syndrome resembling ageing. Nature 1997;390:45. 46 Torres,U., et al., Klotho: an antiaging protein involved
in mineral and vitamin D metabolism. Kidney Int 2007;71:730-737. 47 Kurosu, H., et al., Suppression of aging in mice by the
hormone Klotho. Science 2005;309:1829-1833. 48 Invidia, L., et al., The frequency of Klotho KL-VS
polymorphism in a large Italian population, from young subjects to
centenarians, suggests the presence of specific time windows for its effect.
Biogerontology 2010;11:67. 49 Leibrock, C.B., et al., NH4Cl treatment prevents tissue
calcification in klotho deficiency. Clin J Am Soc Nephrol 2015;26:2423-2433. 50 Leibrock, C.B., et al., 1,25(OH)2D3 dependent overt
hyperactivity phenotype in klotho-hypomorphic mice. Sci Rep 2016;6:24879. 51 Dubal, D.B., et al., Life extension factor klotho
enhances cognition. Cell Rep 2014;7:1065-1076. 52 Gold,W., J. Licinio, and M. Pavlatou, Pathological
parainflammation and endoplasmic reticulum stress in depression: potential
translational targets through the CNS insulin, klotho and PPAR-γ
systems. Mol Psychiatry 2013;18:154. 53 Ito, K., Frontiers of model animals for neuroscience: two
prosperous aging model animals for promoting neuroscience research. Exp Anim
2013;62:275-280. 54 Park, S.-J., et al., Inactivation of JAK2/STAT3 signaling
axis and downregulation of M1 mAChR cause cognitive impairment in klotho
mutant mice, a genetic model of aging. Neuropsychopharmacology 2013;38:1426. 55 Nagai, T., et al., Cognition impairment in the genetic
model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J
2003;17:50-52. 56 Chen, C.-D., et al., The antiaging protein Klotho
enhances oligodendrocyte maturation and myelination of the CNS. J Neurosci
2013;33:1927-1939. 57 Abraham, C.R., et al., Small-molecule Klotho enhancers as
novel treatment of neurodegeneration. Future Med Chem 2012;4:1671-1679. 58 BonDurant, L.D. and M.J. Potthoff, Fibroblast Growth
Factor 21: A Versatile Regulator of Metabolic Homeostasis. Annu Rev Nutr
2018;38:173-196. 59 Schumann, G., et al., KLB is associated with alcohol
drinking, and its gene product beta-Klotho is necessary for FGF21 regulation
of alcohol preference. Proc Natl Acad Sci U S A 2016;113:14372-14377. 60 Soberg, S., et al., FGF21, a liver hormone that inhibits
alcohol intake in mice, increases in human circulation after acute alcohol
ingestion and sustained binge drinking at Oktoberfest. Mol Metab
2018;11:96-103. 61 Song,, et al., The Hormone FGF21 Stimulates Water
Drinking in Response to Ketogenic Diet and Alcohol. Cell Metab
2018;27:1338-1347 e4. 62 Talukdar, S., et al., FGF21 Regulates Sweet and Alcohol
Preference. Cell Metab 2016;23:344-9. 63 von Holstein-Rathlou, S. and M.P. Gillum, Fibroblast
growth factor 21: an endocrine inhibitor of sugar and alcohol appetite. J
Physiol 2019;597:3539-3548. 64 Kalueff, A.V., et al., Increased anxiety in mice lacking
vitamin D receptor gene. Neuroreport 2004;15:1271-1274. 65 Kalueff, A.V., et al., Abnormal behavioral organization
of grooming in mice lacking the vitamin D receptor gene. J Neurogenet
2005;19:1-24. 66 Zou, J., et al., Progressive hearing loss in mice with a
mutated vitamin D receptor gene. Audiol Neurootol 2008;13:219-230. 67 Burne, T.H., et al., Developmental vitamin D (DVD)
deficiency alters pup-retrieval but not isolation-induced pup ultrasonic
vocalizations in the rat. Physiol Behav 2011;102:201-204. 68 Burne, T.H., et al., Swimming behaviour and post-swimming
activity in Vitamin D receptor knockout mice. Brain Res Bull 2006;69:74-78. 69 Burne, T.H., et al., Behavioural characterization of
vitamin D receptor knockout mice. Behav Brain Res 2005;157:299-308. 70 Kalueff, A., et al., Increased grooming behavior in mice
lacking vitamin D receptors. Physiol Behav 2004;82:405-409. 71 Kalueff, A.V., et al., Impaired motor performance in mice
lacking neurosteroid vitamin D receptors. Brain Res Bull 2004;64:25-29. 72 Kalueff, A.V., et al., Increased severity of chemically
induced seizures in mice with partially deleted Vitamin D receptor gene.
Neurosci Lett 2006;394:69-73. 73 Sakai, S., et al., Vitamin D receptor signaling enhances
locomotive ability in mice. J Bone Miner Res 2015;30:128-136. 74 Kuningas, M., et al., VDR gene variants associate with
cognitive function and depressive symptoms in old age. Neurobiol Aging
2009;30:466-473. 75 Wrzosek, M., et al., Association between Fok I vitamin D
receptor gene (VDR) polymorphism and impulsivity in alcohol-dependent
patients. Mol Biol Rep 2014;41:7223-7228. 76 Minasyan, A., et al., Neophobia, sensory and cognitive
functions, and hedonic responses in vitamin D receptor mutant mice. J Steroid
Biochem Mol Biol 2007;104:274-280. 77 Glade, M.J., Vitamin D: health panacea or false prophet?
Nutrition 2013;29:37-41. 78 Hedelin, M., et al., Dietary intake of fish, omega-3,
omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of
psychotic-like symptoms in a cohort of 33 000 women from the general
population. BMC Psychiatry 2010;10:38. 79 Jylhä,, et al., Differences in neuroticism and
extraversion between patients with bipolar I or II and general population
subjects or major depressive disorder patients. J Affect Disord
2010;125:42-52. 80 Ubbenhorst, A., et al., Exploring the relationship
between vitamin D and basic personality traits. Psychopharmacology
2011;215:733-737. 81 Voracek, M., Big Five personality factors and suicide
rates in the United States: A state-level analysis. Percept Mot Skills
2009;109:208-212. 82 Hoogendijk, W.J., et al., Depression is associated with
decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in
older adults. Arch Gen Psych 2008;65:508-512. 83 Wilkins, C.H., et al., Vitamin D deficiency is associated
with low mood and worse cognitive performance in older adults. Am J Geriatr
Psychiatry 2006;14:1032-1040. 84 Bertone-Johnson, E.R., Vitamin D and the occurrence of
depression: causal association or circumstantial evidence? Nutr Rev 2009;67:481-492. 85 Jorde, R., et al., Effects of vitamin D supplementation
on symptoms of depression in overweight and obese subjects: randomized double
blind trial. J Intern Med 2008;264:599-609. 86 Shipowick, C.D., et al., Vitamin D and depressive symptoms
in women during the winter: a pilot study. Appl Nurs Res 2009;22:221-225. 87 Lansdowne, A.T. and S.C. Provost, Vitamin D3 enhances
mood in healthy subjects during winter. Psychopharmacology 1998;135:319-323. 88 Herran, A., et al., Can personality traits help us
explain disability in chronic schizophrenia? Psychiatry Clin Neurosci
2006;60:538-545. 89 Petschner,, et al., Downregulation of the Vitamin D
Receptor Regulated Gene Set in the Hippocampus After MDMA Treatment. Front
Pharmacol 2018;9:1373. 90 Shirazi, H.A., et al., 1,25-Dihydroxyvitamin D3
suppressed experimental autoimmune encephalomyelitis through both
immunomodulation and oligodendrocyte maturation. Exp Mol Pathol
2017;102:515-521. 91 Zhen, C., et al., Suppression of murine experimental
autoimmune encephalomyelitis development by 1,25-dihydroxyvitamin D3 with
autophagy modulation. J Neuroimmunol 2015;280:1-7. 92 Lee, W.P., et al., Immunomodulatory Effects of
1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell
Hyporesponsiveness to Myelin-Derived Antigens. J Immunol Res
2016;2016:5392623. 93 Huang, Y.N., et al., 1,25-Dihydroxyvitamin D3 attenuates
endotoxin-induced production of inflammatory mediators by inhibiting MAPK
activation in primary cortical neuron-glia cultures. J Neuroinflammation
2015;12:147. 94 Biggar,H., et al., Vitamin D, chronic kidney disease and
survival: a pluripotent hormone or just another bone drug? Pediatr Nephrol
2011;26:7-18. 95 Brown, A.J. and D.W. Coyne, Vitamin D analogs: new
therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol
2002;1:313-327. 96 Palmer, S.C., et al., Vitamin D compounds for people with
chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev
2009: CD008175. 97 Pavlovic, D., et al., Vitamin d in the patients with
chronic kidney disease: when, to whom and in which form. Mater Sociomed
2015;27:122-124. 98 Zhang, Q., et al., Effect of Vitamin D Receptor
Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic
Review. PLoS One 2016;11:e0147347. 99 Aygun, H., M. Ayyildiz, and E. Agar, Effects of vitamin D
and paricalcitol on epileptogenesis and behavioral properties of WAG/Rij rats
with absence epilepsy. Epilepsy Res 2019;157:106208. 100 Uyanikgil, Y., et al., Inhibitor effect of paricalcitol
in rat model of pentylenetetrazol-induced seizures. Naunyn Schmiedebergs Arch
Pharmacol 2016;389:1117-1122. 101 Grimm, M.O.W., et al., Vitamin D and Its Analogues
Decrease Amyloid-beta (Abeta) Formation and Increase Abeta-Degradation. Int J
Mol Sci 2017;18:12. 102 AlJohri, R., M. AlOkail, and S.H. Haq, Neuroprotective
role of vitamin D in primary neuronal cortical culture. Neurological Sci
2019;14:43-48. 103 Shirazi, H.A., et al., 1,25-Dihydroxyvitamin D3 enhances
neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol
Pathol 2015;98:240-245. 104 Kesby, J.P., et al., Developmental vitamin D deficiency
alters dopamine-mediated behaviors and dopamine transporter function in adult
female rats. Psychopharmacology 2010;208:159. 105 Pertile, R.A., X. Cui, and D.W. Eyles, Vitamin D
signaling and the differentiation of developing dopamine systems.
Neuroscience 2016;333:193-203. 106 Cui, X., et al., Vitamin D regulates tyrosine
hydroxylase expression: N-cadherin a possible mediator. Neuroscience
2015;304:90-100. 107 Pertile, R.A.N., et al., Vitamin D regulation of
GDNF/Ret signaling in dopaminergic neurons. FASEB J 2018;32:819-828. 108 Zhang, D., et al., 1alpha,25-Dihydroxyvitamin D3
up-regulates IL-34 expression in SH-SY5Y neural cells. Innate Immun
2017;23:584-591. 109 Patel, and J. Shah, Role of Vitamin D in Amyloid
clearance via LRP-1 upregulation in Alzheimer's disease: A potential
therapeutic target? J Chem Neuroanat 2017;85:36-42. 110 Pierucci, F., et al., Vitamin D3 protects against Abeta
peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A
role for S1P1/p38MAPK/ATF4 axis. Neuropharmacology 2017;116:328-342. 111 Veenstra, T.D., et al., Effects of 1,25-dihydroxyvitamin
D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res 1997;99:53-60. 112 Izquierdo, M.C., et al., Klotho, phosphate and
inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant
2012;27:iv6-iv10. 113 Veenstra, T.D., A.J. Windebank, and R. Kumar,
1,25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein
kinase C, and transforming growth factor-beta2 in neuroblastoma cells.
Biochem Biophys Res Commun 1997;235: 15-18. 114 Khanal, R.C. and I. Nemere, Regulation of intestinal
calcium transport. Annu Rev Nutr 2008. 28:179-196. 115 Ramasamy, I., Recent advances in physiological calcium
homeostasis. Clin Chem Lab M 2006;44: 237-273. 116 Shumilina, E., et al., Regulation of calcium signaling
in dendritic cells by 1,25-dihydroxyvitamin D3. FASEB J 2010;24:1989-1996. 117 Celio, M., et al., Monoclonal antibodies directed
against the calcium binding protein Calbindin D-28k. Cell Calcium
1990;11:599-602. 118 Obradovic, D., et al., Cross‐talk of vitamin D and
glucocorticoids in hippocampal cells. J Neurochem 2006;96:500-509. 119 Reichrath, J., R. Saternus, and T. Vogt, Challenge and
perspective: the relevance of ultraviolet (UV) radiation and the vitamin D
endocrine system (VDES) for psoriasis and other inflammatory skin diseases.
Photochem Photobiol Sci 2017;16:433-444. 120 Reichrath, J., et al., Targeting the vitamin D endocrine
system (VDES) for the management of inflammatory and malignant skin diseases:
An historical view and outlook. Rev Endocr Metab Disord 2016;17:405-417.
Synthetic VDR agonists
https://doi.org/10.1080/09674845.2013.11669951
https://doi.org/10.3390/nu7010443
https://doi.org/10.1159/000368472
https://doi.org/10.1016/S0303-7207(99)00039-8
https://doi.org/10.1159/000343403
https://doi.org/10.1152/ajprenal.00302.2004
https://doi.org/10.1146/annurev.med.051308.111339
https://doi.org/10.1038/nrneph.2013.111
https://doi.org/10.1016/j.ijcard.2014.08.033
https://doi.org/10.1146/annurev-physiol-030212-183727
https://doi.org/10.1159/000355737
https://doi.org/10.1159/000355730
https://doi.org/10.1007/s00424-013-1340-y
https://doi.org/10.1159/000442602
https://doi.org/10.1159/000495393
https://doi.org/10.1002/1873-3468.13494
https://doi.org/10.1515/jbcpp-2017-0121
https://doi.org/10.1186/1471-2474-3-16
https://doi.org/10.1210/endo.138.11.5545
https://doi.org/10.1023/A:1005772432465
https://doi.org/10.1016/j.hkjn.2015.09.119
https://doi.org/10.1093/ajcn/80.6.1717S
https://doi.org/10.1096/fj.01-0433rev
https://doi.org/10.1007/s10067-011-1880-5
https://doi.org/10.1002/eji.200838216
https://doi.org/10.1016/S1262-3636(07)70200-8
https://doi.org/10.1096/fj.13-239277
https://doi.org/10.1016/j.mce.2017.05.035
https://doi.org/10.1007/s11920-009-0003-3
https://doi.org/10.1037/0022-3514.95.1.212
https://doi.org/10.1016/j.jsbmb.2004.03.062
https://doi.org/10.1097/WNR.0000000000000328
https://doi.org/10.1016/j.jchemneu.2004.08.006
https://doi.org/10.4049/jimmunol.170.11.5382
https://doi.org/10.1359/jbmr.2003.18.3.579
https://doi.org/10.1210/jc.87.6.2967
https://doi.org/10.1097/NEN.0b013e31827f4fcc
https://doi.org/10.1210/jc.86.2.888
https://doi.org/10.1016/j.jsbmb.2017.09.008
https://doi.org/10.1126/science.6977846
https://doi.org/10.1038/36285
https://doi.org/10.1038/sj.ki.5002163
https://doi.org/10.1126/science.1112766
https://doi.org/10.1007/s10522-009-9229-z
https://doi.org/10.1681/ASN.2014030230
https://doi.org/10.1038/srep24879
https://doi.org/10.1016/j.celrep.2014.03.076
https://doi.org/10.1038/mp.2012.167
https://doi.org/10.1538/expanim.62.275
https://doi.org/10.1038/npp.2013.39
https://doi.org/10.1096/fj.02-0448fje
https://doi.org/10.1523/JNEUROSCI.2080-12.2013
https://doi.org/10.4155/fmc.12.134
https://doi.org/10.1146/annurev-nutr-071816-064800
https://doi.org/10.1073/pnas.1611243113
https://doi.org/10.1016/j.molmet.2018.03.010
https://doi.org/10.1016/j.cmet.2018.04.001
https://doi.org/10.1016/j.cmet.2015.12.008
https://doi.org/10.1113/JP277117
https://doi.org/10.1097/01.wnr.0000129370.04248.92
https://doi.org/10.1080/01677060590949683
https://doi.org/10.1159/000115431
https://doi.org/10.1016/j.physbeh.2010.11.006
https://doi.org/10.1016/j.brainresbull.2005.10.014
https://doi.org/10.1016/j.bbr.2004.07.008
https://doi.org/10.1016/j.physbeh.2004.04.010
https://doi.org/10.1016/j.brainresbull.2004.04.015
https://doi.org/10.1016/j.neulet.2005.10.007
https://doi.org/10.1002/jbmr.2317
https://doi.org/10.1016/j.neurobiolaging.2007.07.001
https://doi.org/10.1007/s11033-014-3607-6
https://doi.org/10.1016/j.jsbmb.2007.03.032
https://doi.org/10.1016/j.nut.2012.05.010
https://doi.org/10.1186/1471-244X-10-38
https://doi.org/10.1016/j.jad.2010.01.068
https://doi.org/10.1007/s00213-011-2175-x
https://doi.org/10.2466/pms.109.1.208-212
https://doi.org/10.1001/archpsyc.65.5.508
https://doi.org/10.1097/01.JGP.0000240986.74642.7c
https://doi.org/10.1111/j.1753-4887.2009.00220.x
https://doi.org/10.1111/j.1365-2796.2008.02008.x
https://doi.org/10.1016/j.apnr.2007.08.001
https://doi.org/10.1007/s002130050517
https://doi.org/10.1111/j.1440-1819.2006.01577.x
https://doi.org/10.3389/fphar.2018.01373
https://doi.org/10.1016/j.yexmp.2017.05.015
https://doi.org/10.1016/j.jneuroim.2015.01.012
https://doi.org/10.1155/2016/5392623
https://doi.org/10.1186/s12974-015-0370-0
https://doi.org/10.1007/s00467-010-1526-x
https://doi.org/10.2165/00024677-200201050-00004
https://doi.org/10.1002/14651858.CD005633.pub2
https://doi.org/10.5455/msm.2015.27.122-124
https://doi.org/10.1371/journal.pone.0147347
https://doi.org/10.1016/j.eplepsyres.2019.106208
https://doi.org/10.1007/s00210-016-1273-z
https://doi.org/10.3390/ijms18122764
https://doi.org/10.1016/j.ensci.2018.12.004
https://doi.org/10.1016/j.yexmp.2015.02.004
https://doi.org/10.1007/s00213-009-1717-y
https://doi.org/10.1016/j.neuroscience.2016.07.020
https://doi.org/10.1016/j.neuroscience.2015.07.048
https://doi.org/10.1096/fj.201700713R
https://doi.org/10.1177/1753425917725391
https://doi.org/10.1016/j.jchemneu.2017.06.007
https://doi.org/10.1016/j.neuropharm.2017.01.003
https://doi.org/10.1016/S0165-3806(96)00196-4
https://doi.org/10.1093/ndt/gfs426
https://doi.org/10.1006/bbrc.1997.6718
https://doi.org/10.1146/annurev.nutr.010308.161202
https://doi.org/10.1515/CCLM.2006.046
https://doi.org/10.1096/fj.09-142265
https://doi.org/10.1016/0143-4160(90)90014-L
https://doi.org/10.1111/j.1471-4159.2005.03579.x
https://doi.org/10.1039/C6PP00280C
https://doi.org/10.1007/s11154-016-9353-4